Research ArticleClinical Investigations
Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan)
Donald G. Grosset, Klaus Tatsch, Wolfgang H. Oertel, Eduardo Tolosa, Nin Bajaj, Andreas Kupsch, John T. O’Brien, John Seibyl, Zuzana Walker, Paul Sherwin, Chris Chen and Igor D. Grachev
Journal of Nuclear Medicine August 2014, 55 (8) 1281-1287; DOI: https://doi.org/10.2967/jnumed.114.138032
Donald G. Grosset
1Institute of Neurological Sciences, Department of Neurology, Southern General Hospital, University of Glasgow, Glasgow, Scotland, United Kingdom
Klaus Tatsch
2Department of Nuclear Medicine, Municipal Hospital Karlsruhe, Inc., Karlsruhe, Germany
Wolfgang H. Oertel
3Department of Neurology, Philipps-University of Marburg, Marburg, Germany
Eduardo Tolosa
4Neurology Service, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain
Nin Bajaj
5Department of Clinical Neurology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
Andreas Kupsch
6Department of Neurology and Stereotactic Neurosurgery, Otto-von-Guericke-University, Magdeburg, Germany
John T. O’Brien
7Department of Psychiatry, University of Cambridge, and Cambridgeshire and Peterborough Foundation NHS Foundation Trust, Cambridge, United Kingdom
John Seibyl
8The Institute for Neurodegenerative Disorders, New Haven, Connecticut
Zuzana Walker
9Mental Health Sciences Unit, University College London, Bloomsbury Campus, London, United Kingdom
10North Essex Partnership NHS Foundation Trust, Essex, United Kingdom
Paul Sherwin
11Life Sciences, GE Healthcare, Princeton, New Jersey; and
Chris Chen
12H2O Clinical, LLC, Hunt Valley, Maryland
Igor D. Grachev
11Life Sciences, GE Healthcare, Princeton, New Jersey; and
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 55, Issue 8
August 1, 2014
Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan)
Donald G. Grosset, Klaus Tatsch, Wolfgang H. Oertel, Eduardo Tolosa, Nin Bajaj, Andreas Kupsch, John T. O’Brien, John Seibyl, Zuzana Walker, Paul Sherwin, Chris Chen, Igor D. Grachev
Journal of Nuclear Medicine Aug 2014, 55 (8) 1281-1287; DOI: 10.2967/jnumed.114.138032
Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan)
Donald G. Grosset, Klaus Tatsch, Wolfgang H. Oertel, Eduardo Tolosa, Nin Bajaj, Andreas Kupsch, John T. O’Brien, John Seibyl, Zuzana Walker, Paul Sherwin, Chris Chen, Igor D. Grachev
Journal of Nuclear Medicine Aug 2014, 55 (8) 1281-1287; DOI: 10.2967/jnumed.114.138032